Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Other Non-Current Liabilities: 2019-2024

Historic Other Non-Current Liabilities for Beam Therapeutics (BEAM) over the last 6 years, with Dec 2024 value amounting to $5.4 million.

  • Beam Therapeutics' Other Non-Current Liabilities rose 27.14% to $6.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.7 million, marking a year-over-year increase of 27.14%. This contributed to the annual value of $5.4 million for FY2024, which is 98.46% up from last year.
  • According to the latest figures from FY2024, Beam Therapeutics' Other Non-Current Liabilities is $5.4 million, which was up 98.46% from $2.7 million recorded in FY2023.
  • Over the past 5 years, Beam Therapeutics' Other Non-Current Liabilities peaked at $31.4 million during FY2021, and registered a low of $2.1 million during FY2020.
  • For the 3-year period, Beam Therapeutics' Other Non-Current Liabilities averaged around $6.9 million, with its median value being $5.4 million (2024).
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first surged by 1,410.21% in 2021, then crashed by 78.15% in 2023.
  • Beam Therapeutics' Other Non-Current Liabilities (Yearly) stood at $2.1 million in 2020, then soared by 1,410.21% to $31.4 million in 2021, then tumbled by 60.27% to $12.5 million in 2022, then tumbled by 78.15% to $2.7 million in 2023, then spiked by 98.46% to $5.4 million in 2024.